Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRA-ZIDE vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydra-Zide is a combination of hydrochlorothiazide (thiazide diuretic) and hydralazine (direct vasodilator). Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing electrolyte reabsorption and increasing urine output. Hydralazine relaxes arteriolar smooth muscle, decreasing systemic vascular resistance and afterload.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Treatment of hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Oral, 1 tablet (25 mg hydrochlorothiazide / 50 mg hydralazine) twice daily, titrated up to maximum of 2 tablets twice daily based on blood pressure response.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); thiazide: 6-15 hours.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide is not extensively metabolized; eliminated unchanged primarily by renal tubular secretion. Hydralazine undergoes extensive hepatic metabolism via acetylation (N-acetyltransferase) and hydroxylation, with glucuronidation and sulfation.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 50-70% of hydralazine as metabolites, 30-40% as parent drug; thiazide: 95% renal as unchanged drug.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Hydralazine: 85-90% bound to albumin; thiazide: 40-70% bound to albumin.
~20% bound to albumin; minimal binding to other plasma proteins.
Hydralazine: 1.5-2.5 L/kg (distributes extensively into tissues); thiazide: 0.2-0.5 L/kg (primarily extracellular fluid).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Hydralazine: 30-50% (oral, variable due to first-pass metabolism); thiazide: 60-80% (oral).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, consider reducing dose (e.g., 1 tablet once daily) or extending interval; avoid if possible. GFR <10 m L/min: Not recommended due to thiazide ineffectiveness.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction (e.g., 1 tablet once daily) and monitor liver function. Child-Pugh C: Contraindicated due to risk of hepatic encephalopathy and hydralazine accumulation.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not approved for pediatric use; safety and efficacy not established. Alternative antihypertensives preferred.
Not recommended; inadequate safety data.
Start at 0.5 tablet (12.5 mg hydrochlorothiazide / 25 mg hydralazine) once or twice daily; titrate slowly. Monitor for hypotension, electrolyte disturbances, and renal function. Maximum dose 2 tablets daily.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
There is no FDA black box warning for Hydra-Zide.
None
May cause a lupus-like syndrome, especially in slow acetylators; discontinue if symptoms appear.,Risk of hypotension, especially with high doses or volume depletion.,Can cause electrolyte imbalances (hypokalemia, hyponatremia, hypercalcemia), monitor serum electrolytes.,May exacerbate renal impairment; use with caution in renal disease.,Possible hypersensitivity reactions including rash, urticaria, and angioedema.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Hypersensitivity to hydrochlorothiazide, hydralazine, or sulfonamide-derived drugs,Severe renal impairment (Cr Cl <30 m L/min),Use with MAO inhibitors (monoamine oxidase inhibitors),Pregnancy (especially second and third trimester) due to hydralazine
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) unless directed. Take with food to reduce gastrointestinal upset. Grapefruit juice may increase drug levels; avoid consumption.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Hydralazine (component of HYDRA-ZIDE) not associated with major malformations; thiazide diuretics (hydrochlorothiazide) have equivocal risk, some studies suggest increased risk of congenital anomalies, but confounded by underlying disease. Second and third trimesters: Thiazides may cause fetal/neonatal electrolyte disturbances, thrombocytopenia, and jaundice; hydralazine may cause neonatal lupus-like syndrome, thrombocytopenia, and hypotension. Use only if clearly needed.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Hydralazine and hydrochlorothiazide are excreted into breast milk in low amounts. M/P ratio not established. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Caution advised; monitor infant for jaundice, electrolyte imbalance, and dehydration.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy-induced increased plasma volume and renal clearance may necessitate dose escalation. Start at lowest effective dose; titrate to blood pressure control. Hydrochlorothiazide is generally avoided as a first-line agent due to volume depletion risks. Hydralazine often used as add-on therapy; dose adjustments based on clinical response.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Monitor serum potassium and creatinine before initiation and periodically; hypokalemia common early, but may cause hyperkalemia in renal impairment. Avoid use in pregnancy (category D). Titrate dose slowly to minimize orthostatic hypotension. Add-on therapy often requires lower doses of each component.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,This drug contains two medicines; your doctor may adjust other medications accordingly.,Stand up slowly to prevent dizziness or fainting.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Avoid alcohol and NSAIDs (ibuprofen, naproxen) unless approved by your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRA-ZIDE vs ALDORIL D50, answered by our medical review team.
HYDRA-ZIDE is a Antihypertensive Combination that works by Hydra-Zide is a combination of hydrochlorothiazide (thiazide diuretic) and hydralazine (direct vasodilator). Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing electrolyte reabsorption and increasing urine output. Hydralazine relaxes arteriolar smooth muscle, decreasing systemic vascular resistance and afterload.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRA-ZIDE and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRA-ZIDE is: Oral, 1 tablet (25 mg hydrochlorothiazide / 50 mg hydralazine) twice daily, titrated up to maximum of 2 tablets twice daily based on blood pressure response.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRA-ZIDE and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRA-ZIDE is classified as Category C. First trimester: Hydralazine (component of HYDRA-ZIDE) not associated with major malformations; thiazide diuretics (hydrochlorothiazide) have equivocal risk, some studies suggest i. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.